Immunosuppressant Drugs Market - Growth, Trends, COVID-19 Impact, and Forecasts (2023 - 2028)

Immunosuppressant Drugs Market - Growth, Trends, COVID-19 Impact, and Forecasts (2023 - 2028)

The immunosuppressant drugs market is expected to register a CAGR of 4.6% during the forecast period.

The COVID-19 pandemic had a significant effect on the market. For instance, according to an article published by PubMed Central in April 2022, there was a 16% global reduction in transplant activity during the initial pandemic, resulting in a substantial impact on the waitlisted patient. Reduced organ transplants meant a reduction in the usage of immunosuppressant drugs as well. However, as the pandemic has subsided, the studied market is expected to grow.

Factors such as the growing prevalence of autoimmune diseases, the rise in organ transplants, and technological advancements in tissue engineering and organ transplantations are expected to enhance the market growth.

The increasing prevalence of autoimmune diseases is a major factor that is expected to enhance the market growth. For instance, according to an article updated by the NCBI in April 2022, around 2.5 million people worldwide have multiple sclerosis, and the article also stated that females are three times more prone to develop the illness than males.

Furthermore, according to an article published by MDPI in July 2022, Rheumatoid arthritis (RA) is considered a common autoimmune illness that manifests majorly as chronic, symmetric, and progressive polyarthritis with a global frequency of 0.3-1.0%. This will lead to increased adoption of immunosuppressant drugs for RA, driving market growth.

Product approval is another major factor for market growth. For instance, in February 2022, China’s National Medical Products Administration (NMPA) approved GlaxoSmithKline’s Benlysta for the treatment of adult patients with active lupus nephritis (LN) in China.

While growth is expected, stringent regulatory processes are expected to hinder the market growth.

Systemic autoimmune diseases are those where autoantigens can be found in almost any type of cell in the body, for example, DNA or protein complexes. As a result, pathological damage involves many different organs and tissues. The increasing prevalence of systemic autoimmune diseases such as rheumatoid arthritis, systemic lupus erythematosus, scleroderma, psoriasis, and dermatomyositis are expected to boost market growth.

According to an article published by MDPI in July 2022, in India, the prevalence of Rheumatoid Arthritis was around 0.7%, with almost 10 million persons suffering from the disease. People with rheumatoid arthritis experience fatigue on most days, with over 70% experiencing symptoms similar to chronic fatigue syndrome.

Furthermore, according to an article published by the Annals of Rheumatic Diseases in October 2022, women were more likely to have systemic lupus erythematosus (SLE) than men. The article further stated that the global SLE incidence and newly diagnosed population in women are estimated to be 8.82 (2.4 to 25.99) per 100,000 person-years and 0.34 million annually, respectively. At the regional level, the incidence of SLE in women varied from 2.00 (0.27 to 6.22) per 100,000 person-years in central Asia to 22.99 (5.35 to 53.28) per 100,000 person-years in central Europe.

Moreover, key product launches by market players are also expected to boost segment growth. For instance, in January 2021, FDA approved Lupkynis (voclosporin), an oral drug that is indicated for the treatment of adult patients with active lupus nephritis developed by Aurinia Pharmaceuticals. It is a novel, structurally modified calcineurin inhibitor that acts as an immunosuppressant and binds and inhibits calcineurin.

North America is expected to hold a significant market share in the immunosuppressant drugs market due to the increasing prevalence of autoimmune diseases and the rapid rise in the number of organ transplants in this region.

The increasing prevalence of autoimmune diseases in the region is a major factor that is expected to drive market growth. For instance, according to data updated by the National Institute of Environmental Health Sciences in May 2022, collectively autoimmune diseases affected more than 24 million people in the United States, and an additional eight million people had auto-antibodies, blood molecules that indicate a person’s chance of developing autoimmune disease. Moreover, according to data updated by Statistics Canada in December 2021, 6,087,600 people had arthritis in Canada in 2021.

Furthermore, the rising research spending on autoimmune diseases is also expected to boost the development of immunosuppressant drugs to treat these diseases. For instance, according to data updated by NIH in May 2022, an estimated USD 1,021 million was spent on the research of autoimmune diseases in the United States in 2021, and was expected to rise to USD 1,061 million by 2022.

Increasing organ transplants are another factor contributing to the market growth. For instance, according to data from the Organ Procurement and Transplantation Network in January 2022, 41,354 organ transplants were performed in the United States in 2021, an increase of 5.9 percent over the last year, going over 40,000 for the first time.

The immunosuppressant drugs market is fragmented and consists of several major players. In terms of market share, a few major players dominate the market. Some of the companies which are currently dominating in the market are Astellas Pharma, Inc, Sanofi (Genzyme), Bristol-Myers Squibb Company, Novartis AG, F. Hoffmann-La Roche Ltd, Pfizer Inc, GlaxoSmithKline Plc, Allergan Plc (Abbvie), Accord Healthcare Ltd (Intas Pharmaceuticals), and Viatris Inc. among others.

• The market estimate (ME) sheet in Excel format
• 3 months of analyst support